ERBB2 and breast cancer: As part of a clinical trial conducted by Robertson et al. (NCT03236974), AZD9496 was compared with fulvestrant concerning the effects on changes in ER, progesterone receptors (PR), and Ki-67 biomarkers in patients who were newly diagnosed with ER+ HER2− breast cancer.